Is RXF undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of RXF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate RXF's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate RXF's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RXF?
Key metric: As RXF is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
The above table shows the Price to Book ratio for RXF. This is calculated by dividing RXF's market cap by their current
book value.
What is RXF's PB Ratio?
PB Ratio
15.7x
Book
CA$90.40m
Market Cap
CA$1.40b
RXF key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Book vs Industry: RXF is expensive based on its Price-To-Book Ratio (15.7x) compared to the European Metals and Mining industry average (0.9x).
Price to Book Ratio vs Fair Ratio
What is RXF's PB Ratio
compared to its
Fair PB Ratio?
This is the expected PB Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
RXF PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio
15.7x
Fair PB Ratio
n/a
Price-To-Book vs Fair Ratio: Insufficient data to calculate RXF's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
The above table shows the analyst RXF forecast and predictions for the stock price in 12 month’s time.
Date
Share Price
Average 1Y Price Target
Dispersion
High
Low
1Y Actual price
Analysts
Current
€8.69
€11.24
+29.4%
14.4%
€13.57
€8.14
n/a
10
Nov ’25
€8.85
€11.31
+27.9%
14.7%
€13.40
€8.04
n/a
11
Oct ’25
€7.52
€11.11
+47.9%
14.1%
€13.32
€7.99
n/a
11
Sep ’25
€6.77
€10.64
+57.3%
14.9%
€13.23
€7.94
n/a
11
Aug ’25
€5.93
€10.69
+80.5%
15.8%
€13.38
€8.03
n/a
11
Jul ’25
€4.84
€10.86
+124.1%
16.6%
€13.65
€8.19
n/a
10
Jun ’25
€3.98
€11.01
+176.5%
11.0%
€13.32
€9.44
n/a
9
May ’25
€4.61
€10.76
+133.5%
15.2%
€13.48
€7.30
n/a
10
Apr ’25
€4.04
€10.63
+163.2%
15.6%
€13.51
€7.32
n/a
10
Mar ’25
€3.36
€10.63
+216.5%
15.6%
€13.51
€7.32
n/a
10
Feb ’25
€4.15
€10.61
+155.7%
15.5%
€13.59
€7.37
n/a
10
Jan ’25
€4.46
€10.36
+132.5%
14.6%
€12.47
€7.31
n/a
10
Dec ’24
€4.06
€10.07
+148.3%
15.1%
€12.20
€7.35
n/a
9
Nov ’24
€3.36
€10.26
+205.8%
12.7%
€11.81
€7.57
€8.85
9
Oct ’24
€4.40
€10.37
+135.9%
11.4%
€11.62
€7.45
€7.52
9
Sep ’24
€4.52
€10.30
+128.0%
12.8%
€11.67
€7.48
€6.77
9
Aug ’24
€4.50
€10.30
+128.8%
12.8%
€11.67
€7.48
€5.93
9
Jul ’24
€4.15
€10.56
+154.6%
11.4%
€11.41
€7.54
€4.84
9
Jun ’24
€4.92
€10.70
+117.4%
8.9%
€11.64
€8.22
€3.98
9
May ’24
€6.04
€10.54
+74.5%
9.1%
€11.37
€8.02
€4.61
9
Apr ’24
€5.55
€10.77
+94.1%
9.8%
€11.83
€8.35
€4.04
9
Mar ’24
€4.82
€10.77
+123.5%
9.8%
€11.83
€8.35
€3.36
9
Feb ’24
€5.40
€10.58
+96.2%
11.6%
€11.71
€7.57
€4.15
9
Jan ’24
€4.88
€10.49
+115.1%
12.0%
€11.78
€7.48
€4.46
9
Dec ’23
€5.21
€10.99
+111.1%
12.0%
€12.34
€7.84
€4.06
9
Nov ’23
€4.51
€11.51
+155.4%
12.5%
€12.93
€7.98
€3.36
9
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.